Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: Systematic review and economic model

Health Technology Assessment

Volumn 17, Issue 56, 2013, Pages

  Tappenden, P ^a   Harnan, S ^a   Uttley, L ^a   Mildred, M ^a   Carroll, C ^a   Cantrell, A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAMITOB; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLISTIMETHATE; COLISTIN; CORTICOSTEROID; DORNASE ALFA; GENTAMICIN; MACROLIDE; MUCOLYTIC AGENT; SALBUTAMOL; TOBRAMYCIN; UNCLASSIFIED DRUG; COLISTINMETHANESULFONIC ACID; DRUG DERIVATIVE;

ARTICLE; BRONCHOSPASM; BRONCHUS SECRETION; COST EFFECTIVENESS ANALYSIS; COUGHING; CRACKLE; CYSTIC FIBROSIS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; DRY POWDER; DYSGEUSIA; DYSPHONIA; DYSPNEA; FATIGUE; FEVER; FORCED EXPIRATORY VOLUME; HEADACHE; HEMOPTYSIS; HUMAN; LUNG CONGESTION; LUNG DISEASE; LUNG FUNCTION TEST; LUNG INFECTION; MORTALITY; NAUSEA; NEBULIZATION; NOSE OBSTRUCTION; OROPHARYNX PAIN; PATIENT COMPLIANCE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RHINORRHEA; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; THORAX PAIN; THROAT IRRITATION; TREATMENT OUTCOME; VOMITING; WHEEZING; CHILD; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG EFFECT; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; OUTCOME ASSESSMENT; REVIEW; THERAPEUTIC EQUIVALENCE; UNITED KINGDOM;

ADMINISTRATION, INHALATION; CHILD; COLISTIN; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; DISEASE PROGRESSION; GREAT BRITAIN; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC EQUIVALENCY; TOBRAMYCIN;

EID: 84888593976     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17560     Document Type: Article

References (200)

1. Davies JC, Alton EW, Bush A. Cystic fibrosis. BMJ 2007;335:1255-9. http://dx.doi.org/10.1136/ bmj.39391.713229.AD
2. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100. http://dx.doi.org/10.1002/ppul.10127
3. Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis: report of the UK Cystic Fibrosis Antibiotic Working Group. 3rd edn. Kent: Cystic Fibrosis Trust; 2009.
4. Yi MS, Tsevat J, Wilmott RW, Kotagal UR, Britto MT. The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference? J Pediatr 2004;144:711-18. http://dx.doi.org/10.1016/j. jpeds.2004.02.032
5. Thornton J, Elliott RA, Tully MP, Dodd M, Webb AK. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros 2005;4:239-47. http://dx.doi.org/10.1016/j.jcf.2005.08.003
6. Cystic Fibrosis Trust. UK CF Registry annual data report 2010. London: Cystic Fibrosis Trust; 2011.
7. Gray MA. CFTR is a mechanosensitive anion channel: a real stretch? J Cell Sci 2010;7:1-7.
8. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006;440:477-83. http://dx.doi.org/10.1038/nature04712
9. Mogayzel PJ Jr, Flume PA. Update in cystic fibrosis 2009. Am J Respir Crit Care Med 2010;181:539-44. http://dx.doi.org/10.1164/rccm.200912-1943UP
10. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010;33:2677-83. http://dx.doi.org/10.2337/dc10-1279
11. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005;26:458-61. http://dx.doi. org/10.1183/09031936.05.00009605
12. Griese M, Muller I, Reinhardt D. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 2002;7:79-80.
13. Kosorok MR, Zeng L, West SH, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32:277-87. http://dx.doi.org/10.1002/ppul.2009.abs
14. Moreau-Marquis S, Stanton BA, O'Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther 2008;21:595-9.
15. Costerton JW, Philip S, Stewart E, Reenberg P. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318. http://dx.doi.org/10.1126/science.284.5418.1318
16. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581-8.
17. Henry RL, Millis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-61.
18. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical development of medicinal products for the treatment of cystic fibrosis. 2009. URL: www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2009/12/WC500017055.pdf. (accessed June 2011).
19. Wagener J, Rasouliyan L, Pasta DJ, Mabie J, Morgan W, Konstan MW. Practice patterns for treating respiratory exacerbations in cystic fibrosis. Pediatr Pulmonol 2008;43(Suppl. 31):359.
20. Bilton D, Canny GJ, Conway S, Dumcius S, Hjelte L, Proesmans M, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011;10(Suppl. 2):79-81. http://dx.doi.org/ 10.1016/S1569-1993(11)60012-X
21. Cystic Fibrosis Registry. UK CF Registry Annual Data Report 2008. 2008; URL: www.cftrust.org. uk/aboutcf/publications/cfregistryreports/UK_CF_Registry-Annual_Data_Report_2008.pdf (accessed 1 April 2012).
22. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-6. http://dx.doi.org/10.1183/09031936.00099506
23. Zemanick ET, Harris JK, Conway S, Konstan MW, Marshall B, Quittner AL, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy. J Cyst Fibros 2010;9:1-16. http://dx.doi.org/10.1016/j.jcf.2009.09.003
24. Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2009. London: CF Registry; 2011.
25. Cystic Fibrosis Trust. Funding of clinical care for cystic fibrosis patients is revolutionised. 2011. URL: www.cftrust.org.uk/pressoffice/pressreleases/PR_PbR.doc (accessed July 2011).
26. Henderson AJ. Bronchoalveolar lavage. Arch Dis Child 1994;70:167-9. http://dx.doi.org/10.1136/ adc.70.3.167
27. Consensus conference: management of patients with cystic fibrosis; pulmonary disease and infection guidelines. 2002. Paris.
28. Miller MR, Hankinson J, Brusasco V, Burgos F, Casabur R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. http://dx.doi.org/10.1183/09031936.05.00034805
29. British Thoracic Society. Spirometry in practice. A practical guide to using spirometry in primary care. London: British Thoracic Society; 2005.
30. Knudson RJ, Slatin RC, Lebowitz MD, Burrows B. The maximal expiratory flow-volume, curve normal standards, variability and effects of age. Am Rev Respir Dis 1976;113:589-90.
31. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-87.
32. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy non-smoking adults. Am Rev Respir Dis 1971;103:57-67.
33. Crapo R, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy non-smoking adults. Bull Europ Physiopathol Respir 1982;18:419-25.
34. Cherniak RM, Raber MD. Normal standards for ventilatory function using an automated wedge spirometer. Am Rev Respir Dis 1972;106:38-46.
35. Dalzell AM, Shepherd RW, Dean B, Cleghorn GJ, Holt TL, Francis PJ. Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. J Pediatr Gastroenterol Nutr 1992;15:141-5. http://dx.doi.org/10.1097/00005176-199208000-00007
36. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-9. http://dx.doi.org/10.1016/j.jpeds.2007.03.006
37. Wang EE, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984;311:1653-8. http://dx.doi.org/10.1056/NEJM198412273112602
38. Kunzli N, Ackermann-Liebrich U, Keller R, Perruchoud AP, Schindler C. Variability of FVC and FEV1 due to technician, team, device and subject in an eight centre study: three quality control studies in SAPALDIA. Swiss Study on Air Pollution and Lung Disease in Adults. Eur Respir J 1995;8:371-6.
39. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51. http://dx.doi.org/10.1164/ rccm.200304-505SO
40. Eichinger M, Heussel CP, Kauczor HU, Tiddens H, Puderbach M. Computed tomography and magnetic resonance imaging in cystic fibrosis lung disease. J Magn Reson Imaging 2010;32:1370-8. http://dx.doi.org/10.1002/jmri.22374
41. Brenner DJ, Hall EJ. Computed Tomography: an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84. http://dx.doi.org/10.1056/NEJMra072149
42. Corey M, Levison H, Crozier D. Five-to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis 1976;114:1085-92.
43. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91. http://dx.doi.org/10.1056/NEJM199204303261804
44. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-14. http://dx.doi.org/10.1016/S0022-3476 (97)70025-8
45. Liou TG, Adler FR, FitzSimmons S, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52. http://dx.doi.org/10.1093/aje/ 153.4.345
46. Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:1550-5.
47. Nathanson I, Ramirez-Garnicia G, Wiltrout SA. Decreased attendance at cystic fibrosis centers by children covered by managed care insurance. Res Prac 2005;95:1958-63. http://dx.doi.org/ 10.2105/AJPH.2004.059089
48. Gee L, Abbott J, Conway SP, Etherington C, Webb AK. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55:946-54. http://dx.doi.org/10.1136/thorax.55.11.946
49. Henry B, Aussage P, Grosskopf C, Goehrs JM. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res 2003;12:63-76.
50. Goss CH, Edwards TC, Ramsey BW, Aitken ML, Patrick DL. Patient reported respiratory symptoms in cystic fibrosis. J Cyst Fibros 2009;8:245-52. http://dx.doi.org/10.1016/j.jcf.2009.04.003
51. Goldbeck L, Schmitz TG, Henrich G, Herschbach P. Questions on life satisfaction for adolescents and adults with cystic fibrosis: development of a disease-specific questionnaire. Chest 2003;123:42-8. http://dx.doi.org/10.1378/chest.123.1.42
52. Quittner AL, Sweeney S, Watrous M, Munzenberger P, Bearss K, Gibson NA, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 2000;25:403-14. http://dx.doi.org/10.1093/jpepsy/25.6.403
53. Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol 2003;28:535-45. http://dx.doi.org/10.1093/jpepsy/ jsg044
54. Jaffé A, Francis J, Rosenthal MBA. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420. http://dx.doi.org/10.1016/S0140-6736(05)78360-4
55. Cai Y, Chai D, Wang R, Bai N, Liang BB, Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011; 66:968-78. http://dx.doi.org/10.1093/jac/dkr040
56. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 2011;9:1, 32. http://dx.doi.org/10.1186/1741-7015-9-32
57. Wallis C. Mucolytic therapy in cystic fibrosis. J Roy Soc Med 2001;94(Suppl. 40):17-24.
58. Jarrett J. The economics of cystic fibrosis care in the East of England. PhD thesis. Norwich: University of East Anglia; 2010.
59. Lorian V. Antibiotics in laboratory medicine. London: Williams & Wilkins Press; 1996.
60. Novartis Pharmaceuticals. Colistimethate sodium powder (Colobreathe®) and tobramycin powder for inhalation (TOBI Podhaler®) for the treatment of Pseudomonas lung infection in cystic fibrosis-Novartis submission to NICE. Surrey: Novartis Pharmaceuticals; 2011.
61. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 62, London: BMA and RPS; 2011.
62. National Institute for Health and Care Excellence (NICE). Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis-final scope. 2010; URL: www.nice.org.uk/nicemedia/live/13068/52778/52778.pdf (accessed June 2011).
63. Centre for Reviews and Dissemination. CRD's guidance for undertaking systematic reviews in health care. York: University of York, CRD; 2009.
64. Paiggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJV. Reporting of non-inferiority and equivalence randomized trials. JAMA 2006;295:1152-60.
65. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011;10:54-61. http://dx.doi.org/10.1016/j.jcf.2010.10.003
66. Forest Laboratories UK. Colistimethate sodium powder for inhalation for the treatment of Pseudomonas lung infection in cystic fibrosis-Forest submission to NICE. Kent: Forest Laboratories UK; 2011.
67. Davies JC, Hall P, Francis J, Scott S, Geddes DM, Conway S, et al. A dry powder formulation of colistimethate sodium is safe and well tolerated in adults and children with CF. Cystic Fibrosis Conference 2004.
68. Konstan M, Flume PA, Brockhaus F, Angyalosi G, He E, Geller D. Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa). J Cyst Fibros 2010;9(Suppl. 1):22. http://dx.doi.org/10.1016/S1569-1993(10)60083-5
69. Forest Laboratories UK. A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium and nebulised TNSFI (tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with Pseudomonas aeruginosa lung infection-clinical study report; 2009, pp. 1-8411.
70. Forest Laboratories UK. A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium and nebulised TNSFI (tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. Final protocol no: COLO/DPI/02/06. Kent: Forest Laboratories UK; 2011.
71. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-64. http://dx.doi.org/10.1183/ 09031936.02.00248102
72. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8. http://dx.doi.org/10.1093/jac/19.6.831
73. Chuchalin A, Csiszer E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007;9(Suppl. 1):21-31. http://dx.doi.org/10.2165/00148581-200709001-00004
74. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Drugs 2007;9(Suppl. 1):11-20. http://dx.doi.org/ 10.2165/00148581-200709001-00003
75. Maclusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-8.
76. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
77. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120(Suppl. 3):107-13. http://dx.doi.org/10.1378/chest.120.3_suppl.107S
78. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63. http://dx.doi.org/10.1378/chest.121.1.55
79. Nasr SZ, Gordon D, Sakma, E, Yu X, Christodoulou E, Eckhardt BP, et al. High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients. Pediatr Pulmonol 2006;41:1129-37. http://dx.doi.org/10.1002/ppul.20447
80. Nasr SZ, Sakmar E, Christodoulou E, Eckhardt BP, Streetman DS, Strouse PJ. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatr Pulmonol 2010;45:440-9. http://dx.doi.org/10.1002/ppul.21188
81. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38:314-20. http://dx.doi.org/10.1002/ppul.20097
82. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6. http://dx.doi.org/10.1056/NEJM199306173282403
83. Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8. http://dx.doi.org/10.1002/ppul.21356
84. European Medicines Agency (EMA). Assessment report Tobi Podhaler. 2011; URL: www.ema. europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002155/ WC500110922.pdf (last accessed 11 January 2011).
85. British Society for Antimicrobial Chemotherapy (BSAC). BSAC methods for antimicrobial susceptibility testing. London: BSAC; 2011.
86. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12. http://dx.doi.org/10.1001/jama.273.5.408
87. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982-9. http://dx. doi.org/10.7326/0003-4819-135-11-200112040-00010
88. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6. http://dx.doi.org/10.1136/bmj.323.7303.42
89. ICH Expert Working Group. ICH Harmonised tripartite guideline: Clinical safety data management-definitions and standards for expedited reporting E2A. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 1994; URL: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/ E2A_Guideline.pdf (accessed 1 April 2012).
90. Drummond MF, Sculpher M, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd edn. New York, NY: Oxford University Press; 2005.
91. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997;10:896-900.
92. Iles R, Legh-Smith J, Drummond M, Prevost A, Vowler S. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J Cyst Fibros 2003;2:120-8. http://dx.doi.org/10.1016/S1569-1993(03)00064-X
93. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-8. http://dx.doi.org/10.1136/ thx.42.10.773
94. Grieve R, Thompson S, Normand C, Suri R, Bush A, Wallis C. A cost-effectiveness analysis of rhDNase in children with CF. Int J Technol Assess Health Care 2003;19:71-9.
95. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2011.
96. Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatr 2009;9:55.
97. Rowen D, Brazier J. Estimation of EQ-5D-Y utilities using CFQ. Preliminary Report, September 2010.
98. Cystic Fibrosis Foundation. 2011; URL: www.cff.org/ (accessed September 2011).
99. Department of Health (DoH). NHS reference costs 2009-2010. London: DoH; 2011. URL: www. dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459 (accessed September 2011).
100. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 61, March 2010; URL: http://bnf.org/ (accessed July 2011).
101. Wenninger K, Aussage P, Wahn U, Staab D. The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument. Qual Life Res 2003;12: 77-85.
102. Wille N, Badia X, Bonsel GJ, Burstrom K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res 2010;19:875-86. http://dx.doi.org/10.1007/ s11136-010-9648-y
103. Rowen D, Longworth L. The use of mapping methods to estimate health state utility values. 2011. URL: www.nicedsu.org.uk/TSD%2010%20mapping%20FINAL.pdf (accessed September 2011).
104. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. 2011. URL: www.york.ac.uk/ media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf (accessed August 2011).
105. Taylor R, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. Health Technol Assess 2009;13(8).
106. International Conference on Harmonisation guidelines for the conduct of clinical trials for the registration of drugs. E9: statistical principles for clinical trials. 2012. URL: www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf (accessed January 2012).
107. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred and conceptual framework. Clin Pharmacol Ther 2001;22:485-502.
108. Johnson JA, Connolly MA, Zuberbuhler P, Brown NE. Health-related quality of life for adults with cystic fibrosis: a regression approach to assessing the impact of recombinant human DNase. Pharmacotherapy 2000;20:1167-74. http://dx.doi.org/10.1592/phco.20.15.1167.34583
109. Stahl E, Lindberg A, Jansson SA, Ronmark E, Svensson K, Andersson F, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005;3:56.
110. Yi MS, Britto MT, Wilmott RW, Kotagul UR, Eckman MH, Nielson DW, et al. Health values of adolescents with cystic fibrosis. J Pediatr 2003;142:133-40. http://dx.doi.org/10.1067/ mpd.2003.51
111. Bradley J, Blume S, Stafford M, Balp M, Elborn S. Quality of life and health utility in patients with cystic fibrosis. European Respiratory Society Conference, Barcelona, 18-22 September, 2010.
112. Ketchell RI, Roughton M, Agent P, Gyi K, Hodson ME. Predicting survival in end-stage cystic fibrosis. Respir Med 2009;103:1441-7. http://dx.doi.org/10.1016/j.rmed.2009.04.025
113. Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel P, Dhainaut J, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005;171:158-64. http://dx.doi.org/10.1164/rccm.200405-667OC
114. Simmonds NJ, Macneill SJ, Cullinan P, Hodson ME. Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J 2010;36:1277-83. http://dx.doi.org/10.1183/09031936.00001710
115. Courtney JM, Bradley J, McCaughan J, O'Connor TM, Shortt C, Bredin CP, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 2:525-32. http://dx.doi.org/ 10.1002/ppul.20619
116. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002;21:1271-87. http://dx.doi.org/ 10.1002/sim.1104
117. Augarten A, Akons H, Aviram M, Bentur L, Blau H, Picard E, et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001;5:339-42. http://dx.doi.org/10.1034/j.1399-3046.2001.00019.x
118. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998;113:1230-4. http://dx.doi.org/10.1378/chest.113.5.1230
119. Hayllar KM, Williams SG, Wise AE, Pouria S, Lombard M, Hodson ME, et al. A prognostic model for the prediction of survival in cystic fibrosis. Thorax 1997;52:313-17. http://dx.doi.org/10.1136/ thx.52.4.313
120. Aurora P, Wade A, Whitmore P, Whitehead B. A model for predicting life expectancy of children with cystic fibrosis. Eur Respir J 2000;16:1056-60. http://dx.doi.org/10.1034/j.1399-3003.2000.16f06.x
121. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss C, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:1550-5. http://dx.doi.org/10.1164/rccm.200202-087OC
122. Belkin RA, Henig NR, Singer LG, Chaparro C, Rubenstein RC, Xie SX, et al. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2005;173:659-66. http://dx.doi.org/10.1164/rccm.200410-1369OC
123. George PM, Banya W, Pareek N, Bilton D, Cullinan P. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011;342. http://dx.doi.org/10.1136/bmj. d1008
124. Grutters J, Joore M, Wiegman E, Langendijk H, De RD, Hochstenbag M, et al. Health-related quality of life in patients surviving non-small cell lung cancer. European Society for Therapeutic Radiology and Oncology (ESTRO) 29, Barcelona, Spain, September 2010; S344-5.
125. Polley L, Yaman N, Heaney L, Cardwell C, Murtagh E, Ramsey J, et al. Impact of cough across different chronic respiratory diseases: comparison of two cough-specific health-related quality of life questionnaires. Chest 2008;134:295-302. http://dx.doi.org/10.1378/chest.07-0141
126. Punekar YS, Rodriguez-Roisin R, Sculpher M, Jones P, Spencer M. Implications of chronic obstructive pulmonary disease (COPD) on patients' health status: a western view. Respir Med 2007;101:661-9. http://dx.doi.org/10.1016/j.rmed.2006.06.001
127. Ko Y, Coons SJ. Self-reported chronic conditions and EQ-5D index scores in the US adult population. Curr Med Res Opin 2006;22:2065-71. http://dx.doi.org/10.1185/ 030079906X132622
128. Anyanwu AC, McGuire A, Rogers CA, Murday AJ. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax 2001;56:218-22. http://dx.doi.org/10.1136/ thorax.56.3.218
129. Department of Health (DoH). NHS reference costs 2010-2011. London: DoH; 2012.
130. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York, NY: Oxford University Press; 2006.
131. Conway S. A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium and nebulised TNSFI (Tobramycin Nebuliser Solution for Inhalation, TOBI) in cystic fibrosis patients with Pseudomonas aeruginosa. 2006. National Research Register (NRR) Archive. URL: www.nihr.ac.uk/Profile/Pages/NRRResults.aspx? publication_id=N0436193944
132. Edenborough FP. Assessing total and regional lung deposition of colistin delivered using a dry powder inhaler and a nebuliser device in adult volunteers with cystic fibrosis. 2001. National Research Register (NRR) Archive. URL: www.nihr.ac.uk/Profile/Pages/NRRResults.aspx? publication_id=N0164087242 (last accessed 28 February 2011).
133. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-13. http://dx.doi.org/10.1002/ppul.20594
134. Geller DE, Flume PA, Brockhaus F, Zhang J, Angyalosi G, He E, et al. Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients. J Cyst Fibros 2010;9(Suppl. 1):22. http://dx.doi.org/10.1016/S1569-1993(10)60084-7
135. Konstan M. Safety of tobramycin inhalation powder (TIP) vs tobramycin solution for inhalation in patients with cystic fibrosis. 2006. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/ct2/ show/NCT00388505?term=CTBM100C2302&rank=1 (last accessed 28 February 2011).
136. Konstan MW, Eller DE, Rockhaus F, Hang J, Ngyalosi G. Tobramycin inhalation powder is effective and safe in the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in patients with cystic fibrosis. Am J Respir Crit Care Med 2009;179:A1186.
137. Le Brun PPH, De Boer AH, Mannes GPM, de Fraeture DMI, Brimicombe RW, Touw DJ, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2: Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002;54:25-32.
138. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124:360-6. http://dx.doi.org/10.1378/chest.124.1.360
139. Novartis Pharmaceuticals. A randomized, double-blind, placebo-controlled, multi-center Phase III Study in cystic fibrosis (CF) subjects to assess efficacy, safety and pharmacokinetics of tobramycin inhalation powder from a modified manufacturing process (TIPnew). 2009. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00918957 (last accessed 28 February 2011).
140. A study of tobramycin inhalation powder from a modified manufacturing process versus placebo (EDIT). 2009. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00918957 (last accessed 28 February 2011).
141. Novartis Pharmaceuticals. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects. 2005. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00125346 (last accessed 28 February 2011).
142. Novartis Pharmaceuticals. Tobramycin inhalation powder (tip) in cystic fibrosis subjects. 2005. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00125346 (last accessed 28 February 2011).
143. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 2004;3:23-8. http://dx.doi.org/10.1016/j.jcf.2003.12.005
144. Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 2007;6: 284-92. http://dx.doi.org/10.1016/j.jcf.2006.10.010
145. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making. University of Sheffield, Decision Support Unit; 2011; pp. 1-24.
146. Alothman GA, Alsaadi MM, Ho BL, Ho SL, Dupuis A, Corey M, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122:930-4. http://dx.doi.org/10.1378/chest.122.3.930
147. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 2000;44:809-13. http://dx.doi.org/10.1128/AAC.44.4.809-813.2000
148. Denk O, Coates AL, Keller M, Leung K, Green M, Chan J, et al. Lung delivery of a new tobramycin nebuliser solution (150 mg/1.5 ml) by an investigational eFlow nebuliser is equivalent to TOBI but in a fraction of time. J Cyst Fibros 2009;8(Suppl. 2):66. http://dx.doi.org/10.1016/ S1569-1993(09)60261-7
149. Mazurek H. A Study comparing the efficacy and tolerability of Tobrineb®/Actitob®/Bramitob® versus TOBI®. 2009. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00885365 (last accessed 28 February 2011).
150. Keller M, Coates AL, Griese M, Den, O, Schierholz J, Knoch M. In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150 mg/1.5 ml) administered by the eFlow electronic nebuliser compared to TOBI in the PARI LC PLUS. J Cyst Fibros 2010; 9(Suppl. 1):22. http://dx.doi.org/10.1016/S1569-1993(10)60085-9
151. Nikolaizik WH, Vietzke D, Ratjen F. A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. Can Respir J 2008; 15:259-62.
152. Winnie GB, Cooper JA, Witson J, Cowan RG, Mayer D, Lepow M. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients. Pediatr Infect Dis J 1991;10:381-6. http://dx.doi.org/10.1097/00006454-199105000-00007
153. Poli G, Acerbi D, Pennini R, Soliani RA, Corrado ME, Eichler HG, et al. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Paediatr Drugs 2007;9(Suppl. 1):3-9. http://dx.doi.org/10.2165/00148581-200709001-00002
154. Riethmueller J, Ballmann M, Schroete, TW, Franke P, von BR, Claass A, et al. Tobramycin once-vs. thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009;37:424-31.
155. Rietschel E, Staab D, Vn KS, Merkel N, Heuer H-E, Posselt H-G. Pharmacokinetics of continuous treatment with o.d. or b.i.d. inhalation of tobramycin (TOBI). J Cyst Fibros 2010;9(Suppl. 1):23. http://dx.doi.org/10.1016/S1569-1993(10)60086-0
156. Spencer D. Efficacy and Safety of 28 or 56 Days Treatment With Inhaled Tobramycin Nebuliser Solution for Pseudomonas Aeruginosa Infection in Children With Cystic Fibrosis. 2006. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00391976 (last accessed 28 February 2011).
157. Westerman EM, Boer AH, Touw DJ, Brun PP, Roldaan AC, Frijlink HW, et al. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor. J Aerosol Med Pulm Drug Deliv 2008;21:269-80. http://dx.doi.org/10.1089/jamp.2007.0674
158. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002;19:303-9. http://dx.doi.org/10.1183/09031936.02.00221602
159. Wood PJ, Ioannides-Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, et al. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996;51:369-73. http://dx.doi.org/ 10.1136/thx.51.4.369
160. Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006;5:261-3. http://dx.doi.org/10.1016/j. jcf.2006.05.009
161. Webb AK. An open-label, randomised clinical trial of the efficacy and safety of Tobramycin solution for inhalation and aerosolised Colistin Sulphomethate Sodium in patients with cystic fibrosis. 1999. National Research Register (NRR). URL: www.nihr.ac.uk/Profile/Pages/NRRResults. aspx?publication_id=N0226050348 (last accessed 28 February 2011).
162. Weller P. An open label, randomised clinical trial of the efficacy and safety of Tobramycin solution for inhalation or aerosolised Colistin Sulphomethate Sodium (Colomycin) in patients with cystic fibrosis (CF). 1999. National Research Register (NRR). URL: www.nihr.ac.uk/Profile/Pages/ NRRResults.aspx?publication_id=N0045026034 (last accessed 28 February 2011).
163. Montgomery AB. Phase III randomized study of the inhalation of tobramycin in patients with cystic fibrosis. 2000. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00004829 (last accessed 28 February 2011).
164. Wientzen R, Prestidge CB, Kramer RI. Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy. Am J Dis Child 1980;134:1134-8. http://dx. doi.org/10.1001/archpedi.1980.02130240018007
165. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Doring G, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92. http://dx.doi.org/10.1002/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.3.CO;2-9
166. Al Ansari NA, Foweraker J, Mackeown D, Bilton D. Evaluation of once daily tobramycin versus the traditional three time daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients. Qatar Med J 2006;15:34-8.
167. Ramsey BW, Retsch-Bogart G, Treggiari M. Comparison of two treatment regimens to reduce PA infection in children with cystic fibrosis. 2004. ClinicalTrials. gov database. URL: http://clinicaltrials. gov/show/NCT00097773 (last accessed 28 February 2011).
168. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol 2001;31:367-76. http://dx.doi.org/10.1002/ppul.1060
169. Flume P. Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients. 2011. URL: http://clinicaltrials.gov/show/NCT01270347 (last accessed 28 February 2011).
170. Kassaa B. Pharmacokinetic bioequivalence Study of Nebcinal® 150 mg/3 ml administered by Aeroneb® Idehaler® versus Tobi® 300 mg/5 ml administered by Pari LC Plus®. 2011. URL: http://clinicaltrials.gov/show/NCT01288170 (last accessed 28 February 2011).
171. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005;365:573-8. http://dx.doi. org/10.1016/S0140-6736(05)17906-9
172. Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis.] Pathol Biol 1998;46:449-51.
173. Trapnell BC, Rolfe M, McColley S, Montgomery AB, Moorehead L, Geller D. Fosfomycin/ tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa. Pediatr Pulmonol 2010;45:302.
174. Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive treatment of Pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Paediatr Scand 1985;74:107-13. http://dx.doi.org/10.1111/j.1651-2227.1985.tb10929.x
175. De Boeck K, Smet M, Eggermont E. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication. Pediatr Pulmonol 1989;7:171-3.
176. Martin AJ, Smalley CA, George RH, Gealing DE, Anderson CM. Gentamicin and tobramycin compared in the treatment of mucoid Pseudomonas lung infections in cystic fibrosis. Arch Dis Child 1980;55:604-7. http://dx.doi.org/10.1136/adc.55.8.604
177. McLaughlin FJ, Matthews WJ Jr, Strieder DJ, Sullivan B, Taneja A, Murphy P, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis ticarcillin tobramycin azlocillin tobramycin and azlocillin placebo. J Infect Dis 1983;147:559-67. http://dx.doi.org/10.1093/infdis/147.3.559
178. Parry MF, Neu HC. A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to Gram-negative bacilli. Am J Med 1978;64:961-6. http://dx.doi.org/10.1016/0002-9343(78)90450-3
179. Pedersen SS, Pressler T, Pedersen M. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Scand J Infect Dis 1986;18:133-7. http://dx.doi.org/10.3109/00365548609032319
180. Wesley AW, Quested C, Edgar BW, Lennon DR. A double-blind comparison of ceftazidime with tobramycin and ticarcillin in the treatment of exacerbations of Pseudomonas chest infection in children with cystic fibrosis. 10th International Cystic Fibrosis Congress, Sydney, Australia, 5-10 March 1988.
181. Taccetti G, Bianchini E, Zavataro L, Campana S, Defilippi G, Ravenni N, et al. Pseudomonas aeruginosa eradication in cystic fibrosis: preliminary data from a randomized multicenter study of two different early antibiotic treatment protocols. Pediatr Pulmonol 2010;45:337-8.
182. Zavataro L, Taccetti G, Cariani L, Ravenni N, Braccini G, Bresci S, et al. Epidemiology of first/new Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2010;9:99e103.29. http://dx.doi.org/10.1016/S1569-1993(10)60111-7
183. Gilead Sciences. Aztreonam for Inhalation Solution (AZLI) vs. Tobramycin Inhalation Solution (TOBI®) in Patients With Cystic Fibrosis & Pseudomonas aeruginosa. 2008. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00757237 (last accessed 28 February 2011).
184. Oermann CM, Assael B, Nakamura C, Boas SR, Bresnik M, Montgomery AB, et al. Aztreonam for inhalation solution (AZLI) vs. tobramycin inhalation solution (TIS), a 6-month comparative trial in cystic fibrosis patients with Pseudomonas aeruginosa. Pediatr Pulmonol 2010;45(Suppl. 33):327.
185. Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41:656-65. http://dx.doi.org/10.1002/ppul.20429
186. Burns JL, Stapp J, Lofland D, Phase AI. Microbiology results from a phase 2 clinical study of aztreonam lysinate for inhalation (AI): a new inhaled antibiotic to treat CF patients with Pseudomonas aeruginosa (PA). J Cyst Fibros 2005;4:S55.
187. McCoy K, Retsch-Bogart G, Gibson RL, Oermann C, Braff M, Montgomery AB. Investigation of susceptibility breakpoints for inhaled antibiotic therapies in cystic fibrosis. Pediatr Pulmonol 2010;341(Suppl. 31):351.
188. Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008;43:47-58.
189. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009;135:1223-32. http://dx.doi.org/10.1378/chest.08-1421
190. Wainwright C, Nakamura C, Geller D, Montgomery AB. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA). J Cyst Fibros 2010; 9(Suppl. 1):22. http://dx.doi.org/10.1016/S1569-1993(10)60082-3
191. Salh B, Bilton D, Dodd M, Abbot J, Webb K. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand J Infect Dis 1992;24:215-18. http://dx.doi.org/10.3109/00365549209052615
192. Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989;8:858-65. http://dx.doi.org/10.1007/BF01963771
193. Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1988;7:171-6. http://dx.doi.org/ 10.1097/00006454-198803000-00008
194. McCoy K, Quittner AL, Oermann C, Gibson RL, Retsch-Bogart GZ, Montgomery AB, et al. Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis. Am J Respir Crit Care Med 2008;178:921-8.
195. Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J. Comparison of drug costs and clinical outcomes with tobramycin solution for inhalation and aztreonam lysine for inhalation in cystic fibrosis. Pediatr Pulmonol 2010;309.
196. Blumer JL, Minkwitz M, Saiman L, San GP, Iaconis J, Melnick D. Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa (PA) or Burkholderia cepacia (BC). Pediatr Pulmonol 2003;(Suppl. 25):294.
197. Richard DA, Nousia-Arvanitakis S, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of anti-Pseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. Pediatr Infect Dis J 1997;16:572-8.
198. Church D, Kanga J, Kuhn R, Rubio T, Haverstock D, Perroncel R, et al. Prospective, double-blind, randomized comparison of ciprofloxacin (CIP) vs ceftazidime/tobramycin (C/T) in the treatment of pediatric cystic fibrosis (CF). Abstr Intersci Conf Antimicrob Agents Chemother 1995;35:332.
199. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr Pulmonol 1988;4:201-4. http://dx.doi.org/10.1002/ppul.1950040403
200. Hoiby N. Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of Pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled Scandinavian multi-centre study. 2006. ClinicalTrials. gov database. URL: http://clinicaltrials.gov/show/NCT00411736 (last accessed 28 February 2011).